The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.
 
Dai Chihara
Honoraria - AstraZeneca/Daiichi Sankyo
Consulting or Advisory Role - ADC Therapeutics; Genmab; Regeneron
Research Funding - Bristol-Myers Squibb/Celgene; Genentech (Inst); Genmab (Inst); Ono Pharmaceutical (Inst)
 
Ayushi Chauhan
No Relationships to Disclose
 
Ruitao Lin
Consulting or Advisory Role - ITM Oncologics; Lilly; Merck Sharp & Dohme, LLC; Monte Rosa Therapeutics
 
Amanda Mason
No Relationships to Disclose
 
Lauren Johnson
No Relationships to Disclose
 
Karmila Murphy
No Relationships to Disclose
 
Jared Henderson
No Relationships to Disclose
 
Luis Malpica
Research Funding - Dizal Pharma (Inst)
 
Chijioke Nze
No Relationships to Disclose
 
Mark Hamilton
No Relationships to Disclose
 
Anath Lionel
No Relationships to Disclose
 
Preetesh Jain
No Relationships to Disclose
 
Paolo Strati
No Relationships to Disclose
 
Ranjit Nair
No Relationships to Disclose
 
Sattva Neelapu
Stock and Other Ownership Interests - Longbow Immunotherapy
Honoraria - MD Education; MJH Life Sciences; Peerview
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Appia Bio; Astellas Pharma; Athenex; Bluebird Bio; Bristol-Myers Squibb; Caribou Biosciences; CARsgen Therapeutics; Chimagen Biosciences; Fosun Kite; Galapagos UK; Gilead Sciences; GlaxoSmithKline; ImmunoACT; Janssen medical Affairs; Jazz Pharmaceuticals; Kite, a Gilead company; ModeX Therapeutics; Morphosys; Orna Therapeutics; Sana Biotechnology; Sellas Life Sciences; Synthekine; Synthekine; Synthekine; Takeda; Takeda
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Cargo Therapeutics; Gilead Sciences; Kite, a Gilead company; Precision Biosciences; Sana Biotechnology
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Jason Westin
Consulting or Advisory Role - Abbvie; Abbvie; ADC Therapeutics; Allogene Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Chugai Pharma; Genentech/Roche; Genmab; Janssen Scientific Affairs; Kite/Gilead; Lyell Immunopharma; Merck; MorphoSys/Incyte; Novartis; Nurix; Regeneron; Seagen
Research Funding - ADC Therapeutics; Allogene Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis; Nurix